Literature DB >> 28474378

Transoral laser microsurgery for treatment for hypopharyngeal cancer in 211 patients.

Bernhard G Weiss1, Friedrich Ihler1, Hendrik A Wolff2, Simon Schneider3, Martin Canis1, Wolfgang Steiner1, Christian Welz1.   

Abstract

BACKGROUND: The oncologic and functional outcome of transoral laser microsurgery (TLM) for primary treatment of hypopharyngeal cancer was examined in a multimodal treatment concept.
METHODS: Two hundred eleven patients with squamous cell carcinoma (SCC) of the hypopharynx (pT1-4a, pN0-2, M0) were treated by TLM +/- neck dissection (88%) +/- (chemo)radiotherapy ([C]RT; 51%). The majority of cases were advanced stages III and IVa (85%).
RESULTS: The 5-year Kaplan-Meier estimates for local control after TLM were pT category-related 88.1%, 74.8%, 77.3%, and 61.8% for pT1-4a tumors. The 5-year estimates of overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) for early stages I and II were 68.2%, 96.7%, and 74.6%, respectively; for stage III they were 65.9%, 83.8%, and 56.4%, respectively; and the rates for stage IVa were 44.5%, 60.7%, and 50.3%, respectively. Overall, 95.7% of the patients maintained regular oral nutrition without feeding tube dependency.
CONCLUSION: Primary TLM in multimodal concepts of treatment (+/- neck dissection, +/- [C]RT) offers favorable oncologic results as compared with other therapeutic regimes.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  carbon dioxide laser; hypopharynx; multimodal treatment concepts; pharyngeal squamous cell carcinoma; transoral laser microsurgery (TLM)

Mesh:

Year:  2017        PMID: 28474378     DOI: 10.1002/hed.24814

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  Oncological and functional outcomes of transoral laser surgery for hypopharyngeal carcinoma.

Authors:  Rodrigo Casanueva; Fernando López; Patricia García-Cabo; César Álvarez-Marcos; José Luis Llorente; Juan Pablo Rodrigo
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-03       Impact factor: 3.236

2.  Prognostic factors after transoral resection of early hypopharyngeal cancer.

Authors:  Keisuke Iritani; Daryl Anne A Del Mundo; Shinobu Iwaki; Kuriko Masuda; Maki Kanzawa; Tatsuya Furukawa; Masanori Teshima; Hirotaka Shinomiya; Koichi Morimoto; Naoki Otsuki; Ken-Ichi Nibu
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-07-17

3.  Factors influencing outcomes in selective neck dissection in 661 patients with head and neck squamous cell carcinoma.

Authors:  Mattis Bertlich; Nina Zeller; Saskia Freytag; Jennifer L Spiegel; Bernhard G Weiss; Martin Canis; Frank Haubner; Friedrich Ihler
Journal:  BMC Surg       Date:  2022-05-19       Impact factor: 2.030

4.  The Second-Look Procedure for Transoral Videolaryngoscopic Surgery for T1 and T2 Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer Patients: Protocol for a Nonrandomized Clinical Trial.

Authors:  Goshi Nishimura; Daisuke Sano; Kenichiro Yabuki; Yasuhiro Arai; Yoshihiro Chiba; Teruhiko Tanabe; Nobuhiko Oridate
Journal:  JMIR Res Protoc       Date:  2017-12-05

Review 5.  Systematic review and meta-analysis of transoral laser microsurgery in hypopharyngeal carcinoma.

Authors:  Ciaran Lane; Rasheda Rabbani; Janice Linton; S Mark Taylor; Norbert Viallet
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-01-14

6.  A prospective clinical trial of the second-look procedure for transoral surgery in patients with T1 and T2 laryngeal, oropharyngeal, and hypopharyngeal cancer.

Authors:  Goshi Nishimura; Daisuke Sano; Yasuhiro Arai; Takashi Hatano; Hideaki Takahashi; Teruhiko Tanabe; Takashi Wada; Daiki Morishita; Nobuhiko Oridate
Journal:  Cancer Med       Date:  2019-10-08       Impact factor: 4.452

Review 7.  Laryngeal Cancer Surgery: History and Current Indications of Transoral Laser Microsurgery and Transoral Robotic Surgery.

Authors:  Stéphane Hans; Robin Baudouin; Marta P Circiu; Florent Couineau; Quentin Lisan; Lise Crevier-Buchman; Jerome R Lechien
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.